{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:42:17Z","timestamp":1761597737539},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Abnormal expression of CD200\/CD200R1 may contribute to the immunologic abnormalities in patients with systemic lupus erythematosus (SLE). This study aimed to assess the function of CD200\/CD200R1and impact of CD200-Fc on dendritic cells in lupus-prone NZB\/WF1 mice. Female NZB\/WF1 mice were treated with CD200-Fc or control for 4 weeks. Plasma samples were collected to measure autoantibody levels. The expression levels of CD200\/CD200R1 in peripheral blood mononuclear cells (PBMCs) and splenocytes were examined. The percentage of CD200\/CD200R1-positive cells in splenocytes from NZB\/WF1 mice was lower than that of C57BL\/6 mice (p\u2009&lt;\u20090.05). The plasma level of anti-dsDNA was significantly higher in NZB\/WF1 mice than C57BL\/6 mice (p\u2009&lt;\u20090.001). However, the anti-dsDNA levels decreased (p\u2009=\u20090.047) after CD200-Fc treatment. Finally, CD200-Fc reduced the levels of IL-6 (p\u2009=\u20090.017) and IL-10 (p\u2009=\u20090.03) in the dendritic cell culture supernatant. This study suggests that the immunosuppressive CD200\/CD200R1 signaling pathway might be involved in the immunopathology of NZB\/WF1 mice; the present results merit further exploration of agents that can modulate the CD200\/CD200FR1 pathway as a therapy for human lupus.<\/jats:p>","DOI":"10.1038\/srep31874","type":"journal-article","created":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T09:59:15Z","timestamp":1471859955000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of CD200-Fc on dendritic cells in lupus-prone NZB\/WF1 mice"],"prefix":"10.1038","volume":"6","author":[{"given":"Yufeng","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,22]]},"reference":[{"key":"BFsrep31874_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrd4227","volume":"13","author":"T Koutsokeras","year":"2014","unstructured":"Koutsokeras, T. & Healy, T. Systemic lupus erythematosus and lupus nephritis. Nat Rev Drug Discov 13, 173\u2013174, 10.1038\/nrd4227 (2014).","journal-title":"Nat Rev Drug Discov"},{"key":"BFsrep31874_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.semarthrit.2004.07.002","volume":"34","author":"Y Sherer","year":"2004","unstructured":"Sherer, Y., Gorstein, A., Fritzler, M. J. & Shoenfeld, Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34, 501\u2013537 (2004).","journal-title":"Semin Arthritis Rheum"},{"key":"BFsrep31874_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/ar2966","volume":"12","author":"JH Fransen","year":"2010","unstructured":"Fransen, J. H. et al. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 12, 207, 10.1186\/ar2966 (2010).","journal-title":"Arthritis Res Ther"},{"key":"BFsrep31874_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nri746","volume":"2","author":"K Shortman","year":"2002","unstructured":"Shortman, K. & Liu, Y. J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2, 151\u2013161, 10.1038\/nri746 (2002).","journal-title":"Nat Rev Immunol"},{"key":"BFsrep31874_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1084\/jem.20082394","volume":"206","author":"C Ohnmacht","year":"2009","unstructured":"Ohnmacht, C. et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 206, 549\u2013559, 10.1084\/jem.20082394 (2009).","journal-title":"J Exp Med"},{"key":"BFsrep31874_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245\u2013252, 10.1038\/32588 (1998).","journal-title":"Nature"},{"key":"BFsrep31874_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1126\/science.1078231","volume":"299","author":"C Pasare","year":"2003","unstructured":"Pasare, C. & Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299, 1033\u20131036, 10.1126\/science.1078231 (2003).","journal-title":"Science"},{"key":"BFsrep31874_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/j.1471-4159.1984.tb12844.x","volume":"43","author":"M Webb","year":"1984","unstructured":"Webb, M. & Barclay, A. N. Localisation of the MRC OX-2 glycoprotein on the surfaces of neurones. J Neurochem 43, 1061\u20131067 (1984).","journal-title":"J Neurochem"},{"key":"BFsrep31874_CR9","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.4049\/jimmunol.171.6.3034","volume":"171","author":"GJ Wright","year":"2003","unstructured":"Wright, G. J. et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 171, 3034\u20133046 (2003).","journal-title":"J Immunol"},{"key":"BFsrep31874_CR10","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.4049\/jimmunol.174.3.1348","volume":"174","author":"HM Cherwinski","year":"2005","unstructured":"Cherwinski, H. M. et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol 174, 1348\u20131356 (2005).","journal-title":"J Immunol"},{"key":"BFsrep31874_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1074-7613(00)00023-6","volume":"13","author":"GJ Wright","year":"2000","unstructured":"Wright, G. J. et al. Lymphoid\/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 13, 233\u2013242 (2000).","journal-title":"Immunity"},{"key":"BFsrep31874_CR12","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1126\/science.290.5497.1768","volume":"290","author":"RM Hoek","year":"2000","unstructured":"Hoek, R. M. et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290, 1768\u20131771 (2000).","journal-title":"Science"},{"key":"BFsrep31874_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/s0002-9440(10)64444-6","volume":"161","author":"C Broderick","year":"2002","unstructured":"Broderick, C. et al. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 161, 1669\u20131677, 10.1016\/s0002-9440(10)64444-6 (2002).","journal-title":"Am J Pathol"},{"key":"BFsrep31874_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1742-2094-9-107","volume":"9","author":"A Lyons","year":"2012","unstructured":"Lyons, A., Downer, E. J., Costello, D. A., Murphy, N. & Lynch, M. A. Dok2 mediates the CD200Fc attenuation of Abeta-induced changes in glia. J Neuroinflammation 9, 107, 10.1186\/1742-2094-9-107 (2012).","journal-title":"J Neuroinflammation"},{"key":"BFsrep31874_CR15","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/art.23378","volume":"58","author":"E Simelyte","year":"2008","unstructured":"Simelyte, E. et al. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheum 58, 1038\u20131043, 10.1002\/art.23378 (2008).","journal-title":"Arthritis Rheum"},{"key":"BFsrep31874_CR16","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/ar3853","volume":"14","author":"Y Li","year":"2012","unstructured":"Li, Y. et al. Aberrant CD200\/CD200R1 expression and function in systemic lupus erythematosus contributes to abnormal T-cell responsiveness and dendritic cell activity. Arthritis Res Ther 14, R123, 10.1186\/ar3853 (2012).","journal-title":"Arthritis Res Ther"},{"key":"BFsrep31874_CR17","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.4049\/jimmunol.170.11.5793","volume":"170","author":"K Kinoshita","year":"2003","unstructured":"Kinoshita, K. et al. Retinoic acid reduces autoimmune renal injury and increases survival in NZB\/WF1 mice. J Immunol 170, 5793\u20135798 (2003).","journal-title":"J Immunol"},{"key":"BFsrep31874_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1189\/jlb.0608374","volume":"85","author":"AE Anderson","year":"2009","unstructured":"Anderson, A. E. et al. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. Journal of leukocyte biology 85, 243\u2013250 (2009).","journal-title":"Journal of leukocyte biology"},{"key":"BFsrep31874_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.clim.2013.04.017","volume":"148","author":"C Llanos","year":"2013","unstructured":"Llanos, C., Mackern-Oberti, J. P., Vega, F., Jacobelli, S. H. & Kalergis, A. M. Tolerogenic dendritic cells as a therapy for treating lupus. Clin Immunol 148, 237\u2013245, 10.1016\/j.clim.2013.04.017 (2013).","journal-title":"Clin Immunol"},{"key":"BFsrep31874_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0065-2776(08)60342-9","volume":"37","author":"AN Theofilopoulos","year":"1985","unstructured":"Theofilopoulos, A. N. & Dixon, F. J. Murine models of systemic lupus erythematosus. Adv Immunol 37, 269\u2013390 (1985).","journal-title":"Adv Immunol"},{"key":"BFsrep31874_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1365-2249.2005.02654.x","volume":"139","author":"Y Nozaki","year":"2005","unstructured":"Nozaki, Y. et al. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB\/WF mice. Clin Exp Immunol 139, 74\u201383, 10.1111\/j.1365-2249.2005.02654.x (2005).","journal-title":"Clin Exp Immunol"},{"key":"BFsrep31874_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1046\/j.1365-2249.1998.00612.x","volume":"112","author":"M Mihara","year":"1998","unstructured":"Mihara, M., Takagi, N., Takeda, Y. & Ohsugi, Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB\/WF1 mice. Clin Exp Immunol 112, 397\u2013402 (1998).","journal-title":"Clin Exp Immunol"},{"key":"BFsrep31874_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1084\/jem.179.1.305","volume":"179","author":"H Ishida","year":"1994","unstructured":"Ishida, H. et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB\/WF1 mice. J Exp Med 179, 305\u2013310 (1994).","journal-title":"J Exp Med"},{"key":"BFsrep31874_CR24","doi-asserted-by":"crossref","unstructured":"Rovin, B. et al. A multicenter, randomized, double\u2010blind, placebo\u2010controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis & Rheumatology (2016).","DOI":"10.1002\/art.39722"},{"key":"BFsrep31874_CR25","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.4049\/jimmunol.163.3.1654","volume":"163","author":"RM Gorczynski","year":"1999","unstructured":"Gorczynski, R. M. et al. An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 163, 1654\u20131660 (1999).","journal-title":"J Immunol"},{"key":"BFsrep31874_CR26","doi-asserted-by":"publisher","first-page":"6880","DOI":"10.4049\/jimmunol.177.10.6880","volume":"177","author":"B Liu","year":"2006","unstructured":"Liu, B. et al. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol 177, 6880\u20136888 (2006).","journal-title":"J Immunol"},{"key":"BFsrep31874_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2050-7771-1-20","volume":"1","author":"T Dhaouadi","year":"2013","unstructured":"Dhaouadi, T. et al. Polymorphisms of Toll-like receptor-4 and CD14 in systemic lupus erythematosus and rheumatoid arthritis. Biomark Res 1, 20, 10.1186\/2050-7771-1-20 (2013).","journal-title":"Biomark Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep31874.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep31874","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep31874.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:10:51Z","timestamp":1672899051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep31874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,22]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,8,31]]}},"alternative-id":["BFsrep31874"],"URL":"https:\/\/doi.org\/10.1038\/srep31874","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,22]]},"assertion":[{"value":"18 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31874"}}